|
Thursday November 29, 2007 |
|
| Morning session: 11.00 - 12.00 |
|
|
|
| Satellite Symposium Biogen Idec |
|
|
|
| Afternoon session: 14.00 - 17.30 |
|
|
|
|
XIII European Charcot Foundation Lecture
New targets of treatment in Multiple Sclerosis |
L. Steinman |
|
|
|
I. What are the ends?
Targets for treatment of Multiple Sclerosis |
|
|
|
|
What is the target of MS treatment: relapse or progression? |
G. Edan |
|
What does pathology suggest on relapses and progression? |
W. Brück |
|
MRI: what should we measure? |
F. Fazekas |
| |
|
| Evening Programme |
|
| Satellite Symposium Bayer Schering Pharma: 18.00 - 20.00 |
|
| Welcome Reception 20.00 - 21.00 |
|
|
|
|
Friday November 30, 2007 |
|
| Morning session: 09.00 - 12.00 |
|
|
|
|
II. The means
Target I
B and T cell activities in MS
The peripheral part of the immune system |
|
|
|
|
B and T cell activity in MS |
R. Hohlfeld |
| New immunosuppressive approaches |
H. Ochi |
| The first data on the Rituximab trial |
J. Antel |
| Cell based antigen-specific approach to induce tolerance in MS |
A. Lutterotti |
| The cytokine network in MS |
K. Selmaj |
| New oral treatments in MS |
G. Comi |
|
|
| Afternoon session: 13.30 - 18.00 |
|
|
|
|
Target II
The blood-brain barrier and inflammation
The entry of inflammation into the brain |
|
|
|
|
Adhesion molecules and chemokines.
How to affect the blood-brain barrier? |
B. Engelhardt |
|
Blocking α4 Integrin - a small molecule approach |
R. Davenport |
| Blockade of chemokine signaling |
F. Zipp |
| Risk benefit ratio of Natalizumab |
O. Stüve |
|
|
|
Target III
Compartmentalization of inflammation in the CNS in
Multiple Sclerosis
The brain as a special immunological compartment |
|
|
|
|
Compartmentalization of inflammation in the central nervous
system: a major mechanism driving progressive Multiple Sclerosis |
E. Meinl |
|
Can stem cells modify inflammation in the brain? |
S. Pluchino |
|
Chemical substances that block macrophages and microglia in the brain |
M. Clanet |
|
Impact on neural cells of immunomodulatory agents that cross the blood-brain barrier |
J. Antel |
|
|
|
Saturday December 1, 2007 |
|
| Morning session: 09.00 - 12.15 |
|
|
|
|
Target IV
Brain tissue injury
Protection and recovery in the brain |
|
|
|
| Mechanisms of inflammation induced tissue injury in MS |
H. Lassmann |
|
Oxidative stress and excitotoxity: a therapeutic issue in Multiple Sclerosis? |
R. Gonsette |
|
Sodium channel blockers and neuroprotection using lamotrigine |
R. Kapoor |
|
Phenytoin protects central axons in EAE. Indications for a new treatment of MS? |
J. Black |
| Protection and restoration of the brain by stem cells |
R. Franklin |
|
|
| Afternoon session: 13.45 - 16.00 |
|
|
|
|
Target V
How to measure treatment effects in MS?
Are the ends clear enough to justify the means? |
|
|
|
| Translation towards personalized medicine in Multiple Sclerosis |
A.Miller |
|
Reconsidering clinical outcomes: relapses, impairment, disability
and beyond |
A. Czaplinski |
|
New MRI measurements for the treatment effects on relapses
and progression |
M. Tintoré |
| Neurophysiology in the measurements of treatment effects |
L. Leocani |
|
The role of biomarkers in treatment effects |
G. Giovannoni |
